U.S. Court in DC Nixes Teva’s Challenge to Medicare Drug Price Negotiations
- November 21, 2025
The U.S. District Court for the District of Columbia rejected November 20 Teva Pharmaceuticals USA’s challenge to the Medicare drug price negotiation program. The court found the company’s claims “either fail on the merits or are unripe” and granted summary judgment to the government.
ARTICLE TAGS
You must be logged in to access this content.